The Changing Landscape of Lymphoma Associated with HIV Infection

Hübel, Kai

doi:10.1007/s11912-020-00973-0

Cited by 18 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Un estudio retrospectivo con 118 participantes que estaban en el régimen de SC-EPOCH-RR mostró una sobrevida global a los 6 años del 90 %, y por su parte el esquema R-EPOCH, en un estudio retrospectivo con 11 pacientes, mostró una sobrevida global a un año del 86 %, lo que nos permite indicar que los regímenes que mostraron una mejor sobrevida global fueron R-CODOX-M/IVAC y R-Hyper-CVAD/HD-MTX (Tabla 1). (13)…”

Section: Resultsunclassified

“…(8,11,12) R-Hyper-CVAD/HD-MTX, un régimen compuesto por rituximab, ciclofosfamida, vincristina, adriamicina, dexametasona, pegaspargase y dosis altas de metotrexato, muestra una sobrevida global a los 2 años de hasta el 93 %. (13) DA-EPOCH-R en pacientes VIH asociados a LB, (28) cuyos compuestos son dosis ajustadas de fosfato de etopósido, prednisona, sulfato de vincristina, ciclofosfamida, clorhidrato de doxorrubicina y rituximab, muestran una sobrevida global al cuarto y séptimo años, del 85 % y 95 %. (8,11,25) R-EPOCH conformado por fosfato de etopósido, prednisona, sulfato de vincristina, ciclofosfamida, clorhidrato de doxorrubicina y rituximab muestra una sobrevida global en el primer y segundo año, de 85 % y 86 % respectivamente.…”

Section: Discussionunclassified

“…(8,11,25) R-EPOCH conformado por fosfato de etopósido, prednisona, sulfato de vincristina, ciclofosfamida, clorhidrato de doxorrubicina y rituximab muestra una sobrevida global en el primer y segundo año, de 85 % y 86 % respectivamente. (12,13,29) SC-EPOCH-RR.-Hubel K, concluye que su uso, un esquema similar a R-EPOCH pero con el uso de un etopósido de corta duración, muestra una sobrevida global a los 6 años del 90 %. (13) Evens et al, (6) concluyeron que la sobrevida global a los 3 años de los pacientes con LB es del 70 % independientemente ya sean VIH negativos o positivos, pero concuerdan que los pacientes que recibieron esquemas que recibieron rituximab versus los esquemas no recibieron rituximab muestran una sobrevida global a los 3 años, del 72 % y 44 % respectivamente.…”

Section: Discussionunclassified

See 2 more Smart Citations

Survival of patients diagnosed with Burkitt-type lymphoma in human immunodeficiency virus carriers.

Piña

Íñiguez

Piña³

et al. 2022

Salud, Ciencia y Tecnología

View full text Add to dashboard Cite

Introducción El linfoma tipo Burkitt (LB) es una de las neoplasias más comunes en pacientes con el virus de inmunodeficiencia humana (VIH), a causa del compromiso inmunitario que presentan. Los pacientes con LB portadoras del VIH presentan una sobrevida que se aproxima al 69% a los dos años. Sin embargo, otros autores mencionan que la sobrevida tan solo llega a ser del 50%, en pacientes en tratamiento antirretroviral (TAR) y quimioterapia. El LB se presenta entre un 50% y un 70% más en personas VIH positiva pues un recuento bajo de linfocitos CD4 aumenta la predisposición a desarrollar LB. La quimioterapia es el método de elección para el tratamiento de linfoma tipo Burkitt en pacientes VIH positivos Objetivo Determinar la sobrevida de pacientes con diagnóstico de Linfoma tipo Burkitt en portadores del Virus de Inmunodeficiencia Humana. Metodología: Revisión bibliográfica de tipo narrativa. Para la búsqueda bibliográfica se usó información recolectada de las siguientes bases de datos: Pubmed en conjunto con la aplicación de operadores booleanos: AND, OR, NOT; y con la ayuda de los términos de búsqueda MeSH como, “Burkitt lymphoma” AND “HIV” AND “Treatment” Resultados: Los pacientes con VIH presentan una mayor incidencia de Linfoma tipo Burkitt debido a su inmunodepresión, por lo cual es importante que se adhieran de manera correcta al tratamiento antirretroviral y a la quimioterapia, ya que la sobrevida de los mimos llega a ser de entre el 45% y 50% a los 2 años del diagnóstico. Palabras clave: Linfoma tipo Burkitt, Tratamiento, VIH

show abstract

Section: Resultsunclassified

Section: Discussionunclassified

See 1 more Smart Citation

Survival of patients diagnosed with Burkitt-type lymphoma in human immunodeficiency virus carriers.

Piña

Íñiguez

Piña³

et al. 2022

Salud, Ciencia y Tecnología

View full text Add to dashboard Cite

show abstract

“…5,6 The frequency of HIV-associated oral PBL in South Africa is about 31.6%, 3,5 which is greater than most comparable studies. 5,7 Whilst the specific prevalence of extra-oral…”

Section: Discussionmentioning

confidence: 99%

Oral versus extra‐oral plasmablastic lymphoma: A comparative analysis of 101 cases

Meer

Perner

Willem

2021

J Oral Pathology Medicine

View full text Add to dashboard Cite

Although originally described as exclusive to the oral cavity in patients with human immunodeficiency virus (HIV)-related immune suppression, plasmablastic lymphomas (PBLs) are reported progressively more in extra-oral sites in HIV and non-HIV immunocompromised and immunocompetent patients. [1][2][3] Whilst oral and extra-oral PBLs are often reported separately, with occasional accounts grouping them together, reports analysing whether this is the same tumour at diverse sites or two different clinical and morphologic tumours are lacking. [1][2][3] This comparative study of 101 oral and extra-oral PBLs in a marked HIV prevalent area in South Africa aims to clarify any distinction between oral and extra-oral PBLs.

show abstract

“…The advent of the Highly Active Antiretroviral Therapy (HAART), led to a significant decrease in the incidence of the most severe systemic conditions associated with AIDS, improving the quality of life of these patients living with HIV/AIDS ( 3 ). However, some human cancers are still frequently diagnosed in HIV-positive patients ( 5 ), and they are categorized into 2 different types: 1) non-AIDS-defining cancers, including Hodgkin lymphomas, which are associated with advanced age, smoking, race and low CD4+ count ( 6 ); and 2) AIDS-defining cancers, usually associated with oncogenic viruses ( 7 ). Regarding AIDS-defining cancers, previous studies indicate Kaposi’s sarcoma as the most prevalent neoplasm, followed by non-Hodgkin lymphomas ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

HIV-related non-Hodgkin lymphomas affecting the oral cavity: a clinicopathologic study of 11 cases

Uchôa¹,

Pontes²,

Souza³

et al. 2022

Med Oral

View full text Add to dashboard Cite

Background HIV-related non-Hodgkin lymphomas of the oral cavity are rare lesions with aggressive clinical behaviour. The aim of this study is to describe the clinicopathological features of a series of HIV-related oral non-Hodgkin lymphomas. Material and Methods Eleven cases of oral lymphomas affecting HIV-positive patients were retrieved from 2012 to 2019. Clinicopathological features regarding age, sex, tumour location, clinical presentation, laboratory findings, disease stage and follow-up were obtained. Histologic, immunohistochemical and in situ hybridization for EBV detection were done for diagnosis confirmation. Overall survival was estimated by Kaplan–Meier curve. Results Males predominated, with a mean age of 40.3 years-old. Maxilla and mandible were the mostly affected. Plasmablastic lymphoma and diffuse large B-cell lymphoma not otherwise specified (NOS) were the main histological types. Lesions presented as reddish ulcerated swellings, representing the first sign of AIDS in six cases. Stage IV were common (7 cases) and the mean HIV viral load was 10,557 copies/mL, with a mean of 266 CD4+ cells/mm3, 1,278 CD8+ cells/mm3 and a CD4+/CD8+ ratio of 0.26. Eight patients died of the disease (72.7%). Overall survival revealed that 78.2% of the patients died after 21 months of follow-up. Conclusions HIV-related oral lymphomas present a poor prognosis usually diagnosed in advanced stages and in our series plasmablastic lymphoma was the most common subtype. Key words: Oral cancer, non-Hodgkin lymphoma, HIV, survival, prognosis.

show abstract

The Changing Landscape of Lymphoma Associated with HIV Infection

Cited by 18 publications

References 73 publications

Survival of patients diagnosed with Burkitt-type lymphoma in human immunodeficiency virus carriers.

Survival of patients diagnosed with Burkitt-type lymphoma in human immunodeficiency virus carriers.

Oral versus extra‐oral plasmablastic lymphoma: A comparative analysis of 101 cases

HIV-related non-Hodgkin lymphomas affecting the oral cavity: a clinicopathologic study of 11 cases

Contact Info

Product

Resources

About